MKI67 and Miyoshi myopathy: These results suggest that for resectable MM, patients with Ki67 ≥ 30% can benefit from TMZ-based adjuvant chemotherapy, which may serve as a potential selection indicator for the population benefiting from adjuvant chemotherapy.